VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2019 | MSI-H status in advanced G/GEJ

Kohei Shitara • 28 Sep 2019
ESMO 2019
Gastrointestinal Cancer
Immuno-Oncology

Kohei Shitara, MD, National Cancer Center Hospital, Kashiwa, Japan, outlines the importance of microsatellite instability-high (MSI-H) status in the treatment of patients with advanced gastric and gastroesophageal junction cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Kohei Shitara

2:09
Future directions of research following the CheckMate-649 trial
Kohei Shitara • 14 Apr 2022
2:29
Overcoming resistance to immunotherapy as first-line therapy in gastric cancer
Kohei Shitara • 7 Apr 2022
4:35
KEYNOTE-062: pembrolizumab vs. chemo in 1L advanced gastric cancer
Kohei Shitara • 20 Jan 2021
1:42
I-O in Gastric/GEJ cancer
Kohei Shitara • 28 Sep 2019

Related Videos

2:54
ILLUMINATE 101: Updates and implications on colorectal cancer
Hani Babiker
3:45
Molecular target therapy in pancreatic and liver cancer
Hani Babiker
3:24
COVID-19 & the management of cancer patients
Alberto F. Sobrero
1:49
HCC clinical trial data from ESMO 2018
Robin Kate Kelley
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals